Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study
about
Vitamin A and retinoid derivatives for lung cancer: a systematic review and meta analysisRetinoic acid post consolidation therapy for high-risk neuroblastoma patients treated with autologous hematopoietic stem cell transplantationHigh-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastomaRapid COJEC versus standard induction therapies for high-risk neuroblastomaRapid COJEC versus standard induction therapies for high-risk neuroblastomaHigh-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastomaIodine-131-meta-iodobenzylguanidine therapy for patients with high-risk neuroblastomaHigh-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastomaTRIM16 acts as a tumour suppressor by inhibitory effects on cytoplasmic vimentin and nuclear E2F1 in neuroblastoma cellsAnti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastomaRole of Retinoic Acid-Metabolizing Cytochrome P450s, CYP26, in Inflammation and CancerNatural killer cells and neuroblastoma: tumor recognition, escape mechanisms, and possible novel immunotherapeutic approachesNeuroblastoma: issues in transplantationNuclear GRP75 binds retinoic acid receptors to promote neuronal differentiation of neuroblastomaCDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma CellsHematopoetic stem cell transplantation in childrenTL-118 and gemcitabine drug combination display therapeutic efficacy in a MYCN amplified orthotopic neuroblastoma murine model--evaluation by MRITemporal proteomics of NGF-TrkA signaling identifies an inhibitory role for the E3 ligase Cbl-b in neuroblastoma cell differentiationOverview and recent advances in the treatment of neuroblastoma.Cytotoxicity of activated natural killer cells against pediatric solid tumors.Adaptive dosing approaches to the individualization of 13-cis-retinoic acid (isotretinoin) treatment for children with high-risk neuroblastoma.Metastatic neuroblastoma cancer stem cells exhibit flexible plasticity and adaptive stemness signaling.Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131 I-Metaiodobenzylguanidine (MIBG).Phase I study of bortezomib in combination with irinotecan in patients with relapsed/refractory high-risk neuroblastoma.Integrating cell-based and clinical genome-wide studies to identify genetic variants contributing to treatment failure in neuroblastoma patientsExtracellular matrix rigidity modulates neuroblastoma cell differentiation and N-myc expressionA single center clinical analysis of children with high-risk neuroblastoma.Treatment of atypical central neurocytoma in a child with high dose chemotherapy and autologous stem cell rescue.Stromal heparan sulfate differentiates neuroblasts to suppress neuroblastoma growth.Outcome for children with metastatic solid tumors over the last four decadesNeuroblastoma in Africa: A Survey by the Franco-African Pediatric Oncology Group.Outcomes for children and adolescents with cancer: challenges for the twenty-first century.YAP promotes tumorigenesis and cisplatin resistance in neuroblastomaRadiation therapy as part of local control of metastatic neuroblastoma: the St Jude Children's Research Hospital experience.An integrated proteomic approach to identifying circulating biomarkers in high-risk neuroblastoma and their potential in relapse monitoringPeripheral blood stem cell support for multiple cycles of dose intensive induction therapy is feasible with little risk of tumor contamination in advanced stage neuroblastoma: a report from the Childrens Oncology GroupNF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome.Prevalence of advanced bone age in a cohort of patients who received cis-retinoic acid for high-risk neuroblastoma.Targeted isotretinoin in neuroblastoma: kinetics, genetics, or absorption.Synergistic activity of fenretinide and the Bcl-2 family protein inhibitor ABT-737 against human neuroblastoma.
P2860
Q21089955-41F7A89D-3729-43C1-828E-53E3B4CE755CQ24186451-1DC2B97B-D859-4E9F-9197-1C69A8D11D29Q24186636-216CC446-20A3-4BC3-A750-E353BD60EE96Q24187922-B4F3C687-A854-488B-9794-BE802C0F16B1Q24197871-1A0356CD-F609-4936-A84F-E6840057B20AQ24200296-9108959D-F489-4F9D-9BAE-D94A6856FE8AQ24201280-CE533BF6-C7AB-4862-9801-F81ED2106374Q24235309-E182C843-0E6B-457E-9648-C0F92F08E2CBQ24297046-A2B1FCF3-6D41-4AF3-9C04-A34457473142Q24602657-B6DAB217-A653-4132-9DE1-83010273F03EQ26800202-5DBB4B62-1943-4927-BB7D-BFE21869E454Q26825652-68FE634A-AB7D-4E87-BC5A-CCE5925CEA5DQ27008197-1F1A3412-F904-4F52-AA38-1EDCF78150B2Q27316571-D8413CF6-F4D9-4EC4-8E31-FA0A886431DFQ27670943-9FA5CF89-7FFD-43AB-9A80-9F969AD2CB09Q28088687-7032B3F8-5474-4800-BF84-2E61BB4110A3Q28540575-CD9B7574-9884-41CF-8235-E90A30FED0FFQ30002320-E0201B02-4FF6-4299-89E2-37B098708738Q30238693-094E861E-314E-47D8-8FBD-31796551FE32Q30503995-DE53812A-8E3B-488B-A851-1E9BAAC7899CQ30532640-41402422-38FC-4305-BA29-63D11CF981ABQ30639268-5820CE4E-D124-4C2E-8FD7-A36308FFA977Q33427090-8BCD793E-8662-4750-8DD7-32181D466BA5Q33441292-2B70DA19-5BEC-4D68-A889-0C757282EEA3Q33645629-3CC72F4A-FDF3-4046-B80D-39E4853B5817Q33702245-4C94DD28-3D06-407C-BD2D-FD06DF0B36FEQ33728327-E1AF4F55-2C49-40A2-990F-29391D7F6894Q33805151-F0F4D21A-1318-4B22-BC5D-BD6917AABAF3Q33808326-249763B6-A1FA-453B-AE6E-5845F7A49F16Q33863587-90018D02-62D5-4DEE-BB14-7926D535874EQ33872797-196AE3C4-8BCB-499F-9DC2-0333291DEE3EQ33897659-E79C8B2D-DCC5-4CF7-BD1C-093240BA3C22Q33913845-EE5ECF1E-903D-4C90-B78D-FB5E3653B547Q33964937-0FD9E2CD-6773-4F1C-AD59-93BF28DFCF27Q33990542-90034765-0721-4A3F-A540-B1905BD69397Q33999779-75EDE720-14C4-4079-BFB8-18A95C54B8D3Q34031980-681621F8-B5CB-4301-8F70-F181F85318BFQ34149469-CDEEF579-8A10-493A-A8DE-86622263E708Q34315331-CF7C741B-BD46-495C-AFDF-5D905AA3E1AFQ34323880-DE2E081B-0A5A-4591-A6F4-9B46184BE0E5
P2860
Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study
description
2009 nî lūn-bûn
@nan
2009 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մարտին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Long-term results for children ...... hildren's oncology group study
@ast
Long-term results for children ...... hildren's oncology group study
@en
Long-term results for children ...... hildren's oncology group study
@nl
type
label
Long-term results for children ...... hildren's oncology group study
@ast
Long-term results for children ...... hildren's oncology group study
@en
Long-term results for children ...... hildren's oncology group study
@nl
prefLabel
Long-term results for children ...... hildren's oncology group study
@ast
Long-term results for children ...... hildren's oncology group study
@en
Long-term results for children ...... hildren's oncology group study
@nl
P2093
P2860
P3181
P356
P1476
Long-term results for children ...... hildren's oncology group study
@en
P2093
Daphne Haas-Kogan
E Stanton Adkins
Hiroyuki Shimada
Judith G Villablanca
Katherine K Matthay
Robert B Gerbing
Robert C Seeger
Wendy B London
P2860
P304
P3181
P356
10.1200/JCO.2007.13.8925
P407
P50
P577
2009-01-26T00:00:00Z